When was Normunity founded?

Normunity was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Normunity located?

Normunity is headquartered in Boston, United States.

Is Normunity a funded company?

Normunity is a funded company, having raised a total of $140M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 25, 2022.

When was the latest funding round of Normunity?

Normunity's latest funding was a $***** Series B round on Jan 13, 2025, with participation from 10 investors.

Where does Normunity rank among its competitors?

Normunity ranks 1053rd amongst 3359 active competitors, of which 1145 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Normunity?

Normunity's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Normunity - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapies for the treatment of cancer. It is developing a pipeline of immune normalizers to restore the immune system’s intrinsic activity to identify and eliminate cancer cells. The lead program is a monoclonal antibody targeting a secreted enzyme that is highly upregulated in multiple human cancers and drives the exclusion of T-cell infiltration in immuno-sensitive tumors.

Website: normunity.com
Social
Email ID: *****@normunity.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Boston, United States

Stage

Series B

Total Funding

$140M in 2 rounds

Latest Funding Round

Series B, Jan 13, 2025, $*****

Investors

Canaan & 10 more

Ranked

1053^rd among 3359 active competitors

Similar Companies

BeiGene & 806 more

View Normunity's full profile

Normunity has raised a total funding of $140M over 2 rounds. Its first funding round was on Oct 25, 2022. Its latest funding round was a Series B round on Jan 13, 2025 for $*****. 10 investors participated in its latest round. Normunity has 11 institutional investors.

Here is the list of recent funding rounds of Normunity:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 13, 2025	5086954	Series B	7825851	9074916	7796955	3076415
Oct 25, 2022	6851989	Series A	9100490	5375748	Canaan	Taiho Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Normunity's funding rounds and investors

The founders of Normunity is Lieping Chen.

Here are the details of Normunity's key team members:

Lieping Chen: Co-Founder of Normunity.
Contact Info: 1 email address

View details of Normunity's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Normunity include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Normunity, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1053rd	Normunity 2020, Boston (United States), Series B	Developer of immunotherapies for the treatment of cancer	$140M	Sanofi Ventures, Samsara BioCapital & 9 others	41/100